CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 81 filers reported holding CUE BIOPHARMA INC in Q4 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $0 | -100.0% | 143 | -85.7% | 0.00% | – |
Q1 2024 | $2,000 | -93.9% | 1,000 | -92.0% | 0.00% | – |
Q4 2023 | $33,000 | +37.5% | 12,460 | +20.7% | 0.00% | – |
Q3 2023 | $24,000 | +200.0% | 10,323 | +381.3% | 0.00% | – |
Q2 2023 | $8,000 | – | 2,145 | +879.5% | 0.00% | – |
Q3 2022 | $0 | – | 219 | +995.0% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 20 | -99.2% | 0.00% | – |
Q1 2022 | $13,000 | -82.9% | 2,660 | -60.3% | 0.00% | – |
Q4 2021 | $76,000 | +81.0% | 6,699 | +135.0% | 0.00% | – |
Q3 2021 | $42,000 | +75.0% | 2,851 | +39.8% | 0.00% | – |
Q2 2021 | $24,000 | -11.1% | 2,039 | -8.5% | 0.00% | – |
Q1 2021 | $27,000 | +800.0% | 2,229 | +998.0% | 0.00% | – |
Q4 2020 | $3,000 | +200.0% | 203 | +322.9% | 0.00% | – |
Q3 2020 | $1,000 | 0.0% | 48 | +17.1% | 0.00% | – |
Q2 2020 | $1,000 | -50.0% | 41 | -62.7% | 0.00% | – |
Q1 2020 | $2,000 | -92.3% | 110 | -93.3% | 0.00% | – |
Q4 2019 | $26,000 | 0.0% | 1,637 | -41.7% | 0.00% | – |
Q3 2018 | $26,000 | -50.0% | 2,808 | -34.8% | 0.00% | – |
Q2 2018 | $52,000 | – | 4,305 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Corriente Advisors, LLC | 1,437,445 | $21,634,000 | 10.97% |
Prosight Management, LP | 709,936 | $10,685,000 | 5.08% |
Voss Capital, LP | 226,573 | $3,410,000 | 1.94% |
Robertson Stephens Wealth Management, LLC | 484,000 | $7,284,000 | 1.79% |
Slate Path Capital LP | 1,483,619 | $22,328,000 | 1.27% |
Nantahala Capital Management | 2,342,216 | $35,250,000 | 1.08% |
SANDERS MORRIS HARRIS LLC | 142,430 | $2,312,000 | 0.63% |
Rock Creek Group, LP | 80,000 | $1,204,000 | 0.62% |
PRECEPT MANAGEMENT LLC | 150,000 | $2,258,000 | 0.55% |
PA Capital LLC | 46,850 | $705,000 | 0.50% |